Provided by Tiger Fintech (Singapore) Pte. Ltd.

Organovo

2.41
+0.04001.69%
Post-market: 2.420.0100+0.41%19:54 EDT
Volume:72.52K
Turnover:170.64K
Market Cap:4.30M
PE:-0.25
High:2.49
Open:2.26
Low:2.25
Close:2.37
Loading ...

Organovo Holdings Inc - Lilly Acquires All Commercial and Ip Rights to Fxr Program

THOMSON REUTERS
·
25 Feb

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

GlobeNewswire
·
25 Feb

Organovo Holdings Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
22 Feb

Organovo: Fiscal Q3 Earnings Snapshot

Associated Press Finance
·
19 Feb

Organovo Holdings Delays Quarterly Report Filing

TIPRANKS
·
15 Feb

Organovo Names Norman Staskey as CFO

MT Newswires Live
·
07 Jan

BRIEF-Organovo Appoints Norman Staskey As CFO

Reuters
·
06 Jan

Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

THOMSON REUTERS
·
06 Jan

Press Release: Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

Dow Jones
·
06 Jan

BRIEF-Organovo Holdings Appoints Norman Staskey As President And CFO

Reuters
·
31 Dec 2024

Organovo Holdings Appoints Norman Staskey as New CFO

TIPRANKS
·
31 Dec 2024

Organovo Holdings Inc - Appoints Norman Staskey as President and CFO

THOMSON REUTERS
·
31 Dec 2024

Organovo Holdings Gains Approval for Key Strategic Moves

TIPRANKS
·
22 Nov 2024

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

GlobeNewswire
·
20 Nov 2024

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

GlobeNewswire
·
13 Nov 2024

ONVO Releases Encouraging Quarterly Results

Zacks Small Cap Research
·
11 Nov 2024